• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    3/10/23 4:36:22 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email
    SC 13G/A 1 upix_sc13g.htm SC 13G/A upix_sc13g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    § 240.13d-1(b), (c), and (d) and AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

     

    (Amendment No. 1)*

     

    UPEXI, INC.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    39959A106

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

    ☐

    Rule 13d-1(b)

     

     

     

     

    ☐

    Rule 13d-1(c)

     

     

     

     

    ☒

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 2 of 6 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Gene Salkind (1)

     

     

    2

    .

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    94,444 (2)

    6.

    SHARED VOTING POWER

     

    2,352,941 (1)

    7.

    SOLE DISPOSITIVE POWER

     

    94,444 (2)

    8.

    SHARED DISPOSITIVE POWER

     

    2,352,941 (1)

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,447,385 (1) (2)

     

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    (SEE INSTRUCTIONS)

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    13.56% (3)

     

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

    (1) Includes shares of Common Stock of the Issuer titled Gene and Catherine Salkind as joint tendency with survivor rights.

     

    (2) Includes options for the purchase of 94,444 of the Issuer’s Common Stock exercisable within 60 days.

     

    (3) Based on 17,960,748 shares of Common Stock as reported in the Issuer’s quarterly report as filed with the Commission on February 15, 2023, and 94,444 shares of the Issuer’s Common Stock issuable upon the exercise of options.

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 3 of 6 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Catherine Salkind (1)

     

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    2,352,941 (1)

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    2,352,941 (1)

     

     9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,352,941

     

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    (SEE INSTRUCTIONS)

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    13.1% (2)

     

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

    (1) Includes shares of Common Stock of the Issuer titled Gene and Catherine Salkind as joint tenancy with survivor rights.

     

    (2) Based on 17,960,748 shares of Common Stock as reported in the Issuer’s quarterly report as filed with the Commission on February 15, 2023.

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 4 of 6 Pages

     

    Item 1.

     

     

     

     

     

     

    (a)

    Name of Issuer: Upexi, Inc.

     

     

     

     

    (b)

    Address of Issuer’s Principal Executive Offices:

     

    17129 US Hwy 19 N.

    Clearwater, FL 33764

     

    Item 2.

     

     

     

     

     

     

    (a)

    Name of Person Filing: Gene and Catherine Salkind

     

     

     

     

    (b)

    Address of Principal Business Office or, if none, Residence:

     

    17129 US Hwy 19 N.

    Clearwater, FL 33764

     

     

    (c)

    Citizenship or Place of Organization: United States of America

     

     

     

     

    (d)

    Title of Class of Securities: Common Stock

     

     

     

     

    (e)

    CUSIP Number: 39959A106

     

    Item 3.

    If this statement is filed pursuant to § 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

     

    (a)

    ☐

    Broker or dealer registered under Section 15 of the Act.

     

     

     

     

     

    (b)

    ☐

    Bank as defined in Section 3(a)(6) of the Act.

     

     

     

     

     

    (c)

    ☐

    Insurance company as defined in Section 3(a)(19) of the Act.

     

     

     

     

     

    (d)

    ☐

    Investment company registered under Section 8 of the Investment Company Act of 1940.

     

     

     

     

     

    (e)

    ☐

    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

     

     

     

     

    (f)

    ☐

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

     

     

     

     

    (g)

    ☐

    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

     

     

     

     

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

     

     

     

     

    (i)

    ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

     

     

     

     

    (j)

    ☐

    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

     

     

     

     

    (k)

    ☐

    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _______________________________________________.

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 5 of 6 Pages

     

    Item 4.

    Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

    (a)

    Amount beneficially owned:

    Gene Salkind  2,447,385

     

     

    Catherine Salkind  2,352,941

     

     

     

     

    (b)

    Percent of class:

    Gene Salkind  13.56%

    Catherine Salkind  13.1%

     

     

     

     

    (c)

    Number of shares as to which the person has:

     

     

    (i)

    Sole power to vote or to direct the vote:

    Gene Salkind 94,444

     

     

     

     

    (ii)

    Shared power to vote or to direct the vote:

    Gene Salkind 2,352,941

    Catherine Salkind 2,352,941

     

     

     

     

    (iii)

    Sole power to dispose or to direct the disposition of:

    Gene Salkind 94,444

     

     

     

     

    (iv)

    Shared power to dispose or to direct the disposition of:

    Gene Salkind 2,352,941

    Catherine Salkind 2,352,941

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    Item 6.

     Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security

     

    Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.

    Certifications.

     

    Not Applicable.

     

     

     

     

     

    CUSIP No. 39959A106

    13G

    Page 6 of 6 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    March 10, 2023

     

    (Date)

     

     

     

    /s/ Gene Salkind

     

    (Signature)

     

     

     

    Gene Salkind

     

    (Name/Title)

     

     

    March 7, 2023

     

    (Date)

     

     

     

    /s/ Catherine Salkind

     

    (Signature)

     

     

     

    Catherine Salkind

     

    (Name/Title)

     

    Attention: Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

     

     

     

     

     

    Get the next $UPXI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    8/4/2025$15.00Buy
    Alliance Global Partners
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Upexi, Inc. with a new price target

    Alliance Global Partners initiated coverage of Upexi, Inc. with a rating of Buy and set a new price target of $15.00

    8/4/25 8:09:26 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

    6/16/25 7:42:40 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026

    Digital Asset Revenue was Approximately $6.1 Million for the Quarter Gross Profit Totaled $8.3 Million, up 183% Year-Over-Year Net Income Increased to $66.7 Million, Compared to a Net Loss of $1.6 Million, Year-over-Year Conference Call Scheduled for today, November 11, 2025, at 5:30 p.m. Eastern Time TAMPA, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced record digital asset revenue for the fiscal first quarter ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025 Total revenue for the quarter was $9.2 mill

    11/11/25 5:25:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Clear Street's Disruptive Technology Conference Convenes this Month in Palm Beach

    Invitation-only event features CEOs, investors and innovators across AI, Digital Assets, Fintech and beyond Keynote speakers Michael Saylor and Eric Trump highlight lineup of thought leaders NEW YORK and PALM BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Clear Street, ("Clear Street", "the Company") a cloud-native financial infrastructure technology firm on a mission to give sophisticated investors access to every asset in every market, will host its Disruptive Technology Conference on November 19–20, 2025, at the Four Seasons Resort Palm Beach, Florida. The two-day, invitation-only event brings together a select group of CEOs, institutional investors and pioneering industry leaders fo

    11/7/25 2:30:00 PM ET
    $ABTC
    $BKKT
    $CLSK
    EDP Services
    Technology
    Finance: Consumer Services
    Finance

    Upexi to Host First Quarter 2026 Earnings Call on November 11th at 5:30 p.m. ET

    TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the first quarter 2026 ended September 30, 2025, on Tuesday, November 11, 2025. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi First Quarter 2026 Earnings CallDate:Tuesday, November 11, 2025Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar Fo

    11/6/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    SEC Filings

    View All

    Upexi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    11/12/25 4:06:12 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Upexi Inc.

    10-Q - UPEXI, INC. (0001775194) (Filer)

    11/12/25 6:10:19 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B3 filed by Upexi Inc.

    424B3 - UPEXI, INC. (0001775194) (Filer)

    11/10/25 6:14:21 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    CSO Rudick Brian Benjamin was granted 400,000 shares, increasing direct ownership by 91% to 838,597 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:09:34 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $799,998 worth of shares (161,943 units at $4.94) and was granted 1,200,000 shares, increasing direct ownership by 154% to 2,246,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:03:08 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Financials

    Live finance-specific insights

    View All

    Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026

    Digital Asset Revenue was Approximately $6.1 Million for the Quarter Gross Profit Totaled $8.3 Million, up 183% Year-Over-Year Net Income Increased to $66.7 Million, Compared to a Net Loss of $1.6 Million, Year-over-Year Conference Call Scheduled for today, November 11, 2025, at 5:30 p.m. Eastern Time TAMPA, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced record digital asset revenue for the fiscal first quarter ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025 Total revenue for the quarter was $9.2 mill

    11/11/25 5:25:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Host First Quarter 2026 Earnings Call on November 11th at 5:30 p.m. ET

    TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the first quarter 2026 ended September 30, 2025, on Tuesday, November 11, 2025. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi First Quarter 2026 Earnings CallDate:Tuesday, November 11, 2025Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar Fo

    11/6/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025

    TAMPA, Fla., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced its financial results for the fiscal year ended June 30, 2025. The annual report is available on either the SEC's website or on Upexi's IR website. Financial Highlights for the Fiscal Year ended June 30, 2025: Revenue totaled $15.8 million.Gross profit totaled approximately $10.7 million, representing a gross margin of 67%.Net loss totaled approximately $13.7 million.As of September 10, 2025, there are 58,893,261 shares of

    9/24/25 5:55:38 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    5/31/23 7:05:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:37:37 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Leadership Updates

    Live Leadership Updates

    View All

    Upexi Welcomes Jon Najarian to the Upexi Advisory Committee

    TAMPA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced the addition of Jon Najarian (Twitter: @jonnajarian) to the Upexi Advisory Committee, joining Arthur Hayes and S◎L Big Brain as founding Upexi Advisory Committee members. Jon Najarian is a highly influential figure in the world of finance, renowned for his deep expertise in options trading and market strategy. A former professional football player, Jon co-founded options trading firm Mercury Trading and later launched financial education company Marke

    10/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care